Free Trial
NASDAQ:ACLX

Arcellx Q4 2023 Earnings Report

Arcellx logo
$63.57 -0.11 (-0.17%)
Closing price 04:00 PM Eastern
Extended Trading
$62.00 -1.57 (-2.47%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcellx EPS Results

Actual EPS
$0.42
Consensus EPS
-$0.53
Beat/Miss
Beat by +$0.95
One Year Ago EPS
-$0.76

Arcellx Revenue Results

Actual Revenue
$63.15 million
Expected Revenue
$20.07 million
Beat/Miss
Beat by +$43.08 million
YoY Revenue Growth
N/A

Arcellx Announcement Details

Quarter
Q4 2023
Time
After Market Closes
Conference Call Date
Wednesday, February 28, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Arcellx's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Arcellx Earnings Headlines

The one deadline Elon can't afford to miss...
For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for it: "Elon Time." But this time... it’s different. A fleet of autonomous robotaxis is scheduled to be unleashed on the streets of Austin, Texas, this June.
See More Arcellx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arcellx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcellx and other key companies, straight to your email.

About Arcellx

Arcellx (NASDAQ:ACLX), together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

View Arcellx Profile

More Earnings Resources from MarketBeat